Showing results (351-360 of 661) with videos related to
Sort By:
Pageof 67
Nature Cancer|April 10, 2023
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumabArash Nabbi, Arnavaz Danesh, Osvaldo Espin-Garcia, et al.Nature Cancer|April 20, 2023
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaKlara Kropivsek, Paul Kachel, Sandra Goetze, et al.Nature Cancer|April 20, 2023
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastomaLuuk van Hooren, Shanna M Handgraaf, Daan J Kloosterman, et al.Nature Cancer|May 1, 2023
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancerAnne I Kraemer, Chloe Chong, Florian Huber, et al.Nature Cancer|July 3, 2020
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profilingSteven M Corsello, Rohith T Nagari, Ryan D Spangler, et al.Nature Cancer|August 18, 2020
Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironmentRonan Thibaut, Pierre Bost, Idan Milo, et al.Nature Cancer|April 22, 2021
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cellsBrett M Stevens, Courtney L Jones, Daniel A Pollyea, et al.Nature Cancer|October 17, 2022
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complexYu-Yi Chu, Mei-Kuang Chen, Yongkun Wei, et al.Nature Cancer|May 26, 2025
Skeletal muscle endothelial dysfunction through the activin A-PGC1α axis drives progression of cancer cachexiaYoung-Mee Kim, Mark A Sanborn, Shaluah Vijeth, et al.Nature Cancer|June 5, 2025
The current and emerging immunotherapy paradigm in small-cell lung cancerKang Qin, Carl M Gay, Lauren A Byers, et al.Pageof 67